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tional researchfindingsbecomeavailable.The statement provides (1) a synopsis of selectedpreanalytical
methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preana-
lyticalmethods, and (3) a list of requiredmethodological information and protocols to bemade available
for publications in the field to foster cross-validation across cohorts and laboratories.
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There is a large concern regarding the lack of reproduc-
ibility of research findings across independent laboratories,
within laboratory settings, and particularly from academic
laboratory settings to industry settings [1–4]. In fact, an
“unspoken rule” among venture capital firms is that 50% of
published studies will not replicate in industrial labs [4] and
the National Institutes of Health (NIH) recently outlined a
plan to address this problem [2]. While there are a large num-
ber of factors contributing to this issue, one key factor is the
substantial variability in study designs, definitions, outcomes,
and analytic models that make replication less likely [1].
While in the discovery phase of science, it is important to
have substantial flexibility; however, as scientific discovery
proceeds closer to the clinic, there is an increased need for
optimization and standardization if these discoveries are to
replicate reliably and pass regulatory authority. Unfortu-
nately, there is oftentimes a disconnect between academic
and industrial laboratories that hampers the movement of
important scientific discovery to clinical practice, and the
generation of standardized methods is one way to bridge
this gap. The purpose of this white paper is the generation
of the first set of guidelines for use in research of blood-
based biomarkers of Alzheimer’s disease (AD).
A major impediment to the therapeutic development and
clinical trial design for AD is the lack of a sensitive, easily-
obtained biomarker of disease [5–7]. Biomarkers of disease
presence, subtypes (i.e., endophenotypes), treatment
response, and progression are needed to advance therapeutic
and preventative opportunities for this rapidly growing
health care crisis [5, 8–13]. Biomarkers are also considereders of the Blood-Based Biomarker Interest Group
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development programs by allowing the validation of
mechanisms of action [14]. They can be employed in clinical
trials to improve diagnostic accuracy in trial participants, thus
allowing cohorts of patients to be enriched with cases of AD
(patient enrichment) [15,16]. In light of this, such markers
may not only be useful in patient identification, selection,
and stratification into clinical trials, but may also be useful
in the identification of novel therapeutic targets.
Over the last two decades, the search for biomarkers that
have diagnostic and prognostic utility in AD has grown
exponentially [6,11] with most work focusing on
neuroimaging and cerebrospinal (CSF) methodologies
[6,11,17]. Advanced neuroimaging and CSF techniques
yield highly accurate diagnostic accuracy within the clinic-
based settings for detecting AD and blood-based biomarkers
represent an approach for enhancing the utility of imaging
and CSF-based modalities by serving as a generalized
screening tool. In fact, it has been proposed that blood-
based methods can serve as the first step in a multistep
diagnostic process [7] as is the case with many other pathol-
ogies, such as cardiovascular diseases, infectious diseases,
and cancer. All screen positives could be referred for neuro-
imaging or CSF assessment for confirmatory purposes (e.g.
for diagnostics or enrollment into clinical trials).
There has been a significant increase in research efforts
examining the potential for blood-based biomarkers of AD.
While the search was largely unsuccessful for decades, recent
work shows promise. In a seminal study, Ray and colleagues
[18] analyzed120plasma-based proteins anddeveloped an al-
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Table 1
Controllable and uncontrollable variables that can impact blood-biomarker
findings within Alzheimer’s disease (AD) studies
Controllable variables Uncontrollable variables
Time of collection Demographic characteristics (age,
sex, ethnicity, or race)
Fasting status APOE ε4 (and other genes)
Needle size and location of draw Smoking status
Handling of tubes (e.g. inversions) Gestation
Tube type and additives Diet
Tube collection order Medications
Time of sample in collection tube Non-AD comorbidities
Centrifugation parameters Alcohol use
Time from collection to freeze Activity level
Temperature of freeze
Freeze-thaw cycles
Aliquot size
Abbreviation: APOE, apolipoprotein E
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all classification accuracy of 89% and accurately identified
81% of mild cognitive impairment (MCI) patients who pro-
gressed to AD within a 2- to 6-year follow-up period [18].
This study represented the first major support for the notion
that an AD biomarker profile could yield excellent accuracy;
however, enthusiasm waned when the findings did not cross-
validate on an independent assay platform [19]. Despite this
initial setback, other groups have continued to identify prom-
ising signals in peripheral blood, suggesting that a blood-
based AD screen may be on the horizon [20–29]. Recently,
data from well-characterized international cohorts have
yielded additional candidate biomarkers and panels [25,30].
In the Texas Alzheimer’s Research and Care Consortium
(TARCC) cohort a serum-based algorithm yielded a 30-
protein profile with a sensitivity of 88% and specificity of
82% for clinical AD diagnosis [31]. The biomarker panel
from baseline plasma collected in the Australia Imaging Bio-
markers and Lifestyle Study of Ageing (AIBL) study con-
sisted of 18 analytes that could distinguish AD from healthy
controls with a sensitivity of 85% and specificity of 93%
[29]. A 17-biomarker panel was associated with the diagnosis
ofMCI andAD in independent cohorts from theUniversity of
Pennsylvania and Washington University in St. Louis, and
two of these analytes were found to be highly correlated
with the CSF t-tau/amyloid-beta (Ab) 42 ratio[30], a strong
predictor of future cognitive decline [32,33]. There have
been several markers consistently altered in AD across
cohorts. As outlined by Kiddle and colleagues [34], an
example of these markers (and number of cohorts they have
been replicated across) include: apolipoprotein E (APOE)
(five cohorts), alpha-2-macroglobulin (five cohorts), comple-
ment C3 (five cohorts), pancreatic prohormone (five cohorts),
serum amyloid P (four cohorts), tumor necrosis factor (two
cohorts), and serum albumin (four cohorts). Many of these
blood-based studies are similar in termsof utilizing a common
analytical platform; however, the biomarker panels obtained
are strikingly different, sharing only a few common analytes.
For example, in the study by Hu and colleagues, several
markers were significantly related to dementia status but in
the opposite direction across cohorts despite the use of the
same analytic platform. Additionally, several studies have
examined the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) proteomic database with different protein signatures
reported [29–31]. The discrepant findings may be due to the
approach employed as the ADNI cohort was utilized as the
validation sample with the protein signatures being
developed in other cohorts (i.e. University of Pennsylvania,
Washington University, AIBL, TARCC). For
comprehensive recent reviews of AD proteomic studies
conducted across a broad range of cohorts see Lista and
colleagues [35] and Kiddle and colleagues [34].
Apart from the fact that different initial panels were tested
(along with different study design), inconsistencies across
study findings could be attributable tomany preanalytical var-
iables, both technical and biological, across studies whichmay have significant impact on the outcomes of the proteomic
analyses. There are numerous possible sources of preanalyti-
cal variations or errors across studies [36]; however, out of
these, we have attempted to highlight only a few important
ones. For example, the selection of study participants in terms
of their ethnicity, lifestyle parameters, and statistically suffi-
cient numbers could be an important source of variation. In
addition, within-subject variation has long been highlighted
as a possible source of concern as participants need to adhere
to certain guidelines during the course of the study [37].
Variations could also be introduced by work staff in terms
of sample collection mode, collection tubes, preparation,
transportation, handling, storage and processing, and different
calibration protocols of the equipment being used [37,38].
One of the most important factors is the fraction of the
blood used for testing (serum vs. plasma) as not only the
abundance of a particular analyte may vary in these
different fractions, but additives such as heparin, citrate, or
ethylenediaminetetraacetic acid (EDTA) influence the
required processing methods and their presence may impact
biomarker stability and detectability [39–41]. Table 1 pre-
sents a list of some of the uncontrollable and controllable vari-
ables that can impact findings from studies of blood-based
biomarkers in AD. The uncontrollable variables should be re-
ported in the methods of protocols and taken into account sta-
tistically, whereas the controllable variables represent
scientific areas where harmonization can occur.
A key step toward generating consistency across studies
with regards to blood-based biomarkers is the establishment
of guidelines for preanalytical protocols [5,42–45] mirroring
the ongoing initiatives for CSFAD biomarkers [17,46,47]. In
fact, such standardization efforts for blood-based biomarkers
have been underway in other fields for some time [24,48–52]
and the European Federation of Clinical Chemistry and
Laboratory Medicine (available at http://efcclm.eu/)
working group reported a substantial reduction in analytic
error with improvements in standardization and reliability
of instruments, reagents, and techniques [53]. Notably, the
STandards for Alzheimer’s Research in Blood biomarkers
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Blood-Based Biomarker Interest Group (BBBIG) to create
a Professional Interest Area (PIA) of the Alzheimer’s Asso-
ciation International Society to Advance Alzheimer’s
Research and Treatment (ISTAART; available at https://act.
alz.org/site/SPageServer?pagename5ISTAART_homepage).
The ultimate goal of this international working group is the
advancement of blood-based biomarkers for the improve-
ment of diagnosis, treatment, and care for those suffering
from AD. This international collaboration recently has pro-
vided an overview regarding the status of the field [5] and
the Alzheimer’s Association and Alzheimer’s Drug Discov-
ery Foundation recently and jointly convened a workshop
to discuss the state of the field [54]. The current work from
the working group was undertaken to (1) summarize selected
methods across many ongoing longitudinal cohorts, (2) take
an initial step toward the provision of guidelines for preana-
lytical methods for studies examining the development and
role of blood-based biomarkers of AD, and (3) provide a min-
imum set of preanalytical variables that must be provided in
publications (within the publication or as a supplement) in
this line of work. Moreover, a set of next-step variables spe-
cific to the elderly and dementia populations to be examined
has been proposed as areas for further research is needed on
this topic to inform the next revision of the current guidelines.2. Ongoing studies
Protocols from 10 (ongoing) AD cohort studies, collabora-
tions, and the National Institute on Aging (NIA) Best Practice
Guidelines (also currently being updated) were reviewed.
These studies were selected as they (1) denote ongoing longi-
tudinal studies with specific foci (including blood-based) in
biomarkers of AD, (2) represent a significant portion of the in-
vestigators and/or publications in the topic area, and (3) were
willing to share detailed protocols regarding blood collection
and processing. These studies also presented established pro-
tocols for requesting biological samples. Those studies or
groups who did not respond to either the request for protocols
or for whom did not provide confidential methods were sub-
sequently excluded. The studies included consisted of the
following: the Alzheimer’s Center Amsterdam [55], Alz-
heimer’s Disease Cooperative Study (ADCS) [56], Alz-
heimer’s Disease Neuroimaging Initiative [57], Australian
Imaging, Biomarkers and Lifestyle study [58,59],
Dominantly Inherited Alzheimer Network (DIAN) [60–62],
Health and Aging Brain among Latino Elders (HABLE)
[63], King’s Dementia Studies [64], NIA Best Practices
[65], TARCC [25,26,31,66], and the Washington University
Adult Children Study (ACS) [67,68].
As reported in Table 1, there is significant consistency, but
also inconsistency and lack of technical details across existing
studies. The TARCC, ADCS, NIA Best Practices, and Alz-
heimer Center Amsterdam studies do not require fasting
blood draws, whereas all others make use of them. On the
other hand, while “overnight fast” was needed for severalstudies, only the DIAN protocol provided a definition for fast-
ing duration (i.e. 8 hours). Many studies provided information
regarding needle gauge to be used, but not all, with 21-gauge
being the most commonly utilized size. Tube type varied
across studies, with little consistency across the category of
serum tube selected. Lavender/purple top EDTA plasma
(K2) was commonly utilized for plasma collection. Centrifu-
gation speed varied across studies by speed, duration, temper-
ature and number of spins, with little consistency noted.
Additionally, the number of revolutions per minute (rpm) in
some studies but g-force in others was utilized for documen-
tation of centrifugation speed. Sample preparation time (total)
was most commonly less than or equal to two hours. Samples
were most commonly stored immediately at 280

C, but
some studies used immediate freeze on dry ice before place-
ment in 280

C or liquid nitrogen. The most common long-
term storage condition was 280

C.3. Guidelines for preanalytical methods
There is a sizable literature documenting the impact of
preanalytical methods on proteomic results, with most of
the errors in laboratory testing coming from outside the an-
alytic phase [37] and the majority originating from the pre-
analytical processing phase [69–72]. Specifically, the role of
preanalytical variables—affecting the quality of the utilized
samples and, consequently, the quality of the data
produced—is frequently disregarded in clinical proteomic
analyses [73]. In this regard, it has been suggested that
46% of the errors in laboratory testing comes from the pre-
analytical phase [74].
If any blood-based AD biomarkers are to move from
research only (discovery phase or cross-validation phase)
to in vitro diagnostic use, standardization of methodologies
is compulsorily required. While there is still a great need for
additional discovery in the area of blood-based biomarkers,
there is also the necessity to “lock-down” or further clini-
cally validate the potential utility of the putative markers
currently available, which is the focus of the current guide-
lines. In the United States, all testing on human samples as
clinical diagnostics must be performed within a regulated
good laboratory practice setting as defined by the Clinical
Laboratory Improvement Amendment of 1988 and other
associated regulatory guidelines [37]. Many procedures for
reaching clinical diagnostic status are determined by stan-
dard protocols, standard operating procedures and national
or international standards, which include the preanalytical
procedures provided by the Clinical Laboratory Standards
Institute (CLSI, available at http://clsi.org/) (formally the
National Committee for Clinical Laboratory Standards),
with strict adherence to such standards being important [37].3.1. Preblood draw
There are a number of patient/participant-related factors
that will impact blood marker results that cannot be
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Some physiological variables to consider include demo-
graphics (age, sex, race/ethnicity), overall health, food and
beverages consumed before collection, chronic drugs/
alcohol use, dietary supplements, smoking, gestation, diet,
exercise, posture or bed rest, and patient medical conditions
and medication status [37,45,48,50,52]. Attempts should be
made to record information related to these variables as
much as possible for appropriate adjustments to be made
during the analysis of results [37,48,50]. As can be seen
from Table 2, most ongoing studies use fasting blood-
collection although the definition of fasting (i.e. 6, 8,
12 hours) is not articulated, despite the fact that fasting dura-
tion has a known impact on many blood-based biomarker
levels. Prior work also suggests that some, but not all, blood
biomarkers exhibit diurnal fluctuations [75–77], which can
have a substantial impact on the clinical significance of
such markers [78]. Standardizing to a morning (before 10
AM fasting) blood draw would address the possible diurnal
fluctuation issues by harmonizing sample collection times
across studies.3.2. Blood collection
There are a number of variables associated with the blood
collection procedure itself that can impact laboratory assay
results. Needle gauge, single-, or multidraw needles, and
needle composition can impact assay results [37], with he-
molysis being a major consideration [79–82]. For example,
in an emergency department setting, the use of a 22-gauge
needle was significantly associated with an increased risk
of hemolysis [83]. Based on prior results, a 21-gauge needle
is preferred [82,84,85]. Needles can be composed of various
materials including stainless steel, aluminum, titanium,
chromium, iron, manganese, nickel, and alloys which may
impact assays that measure various metals within the
blood. A detailed description of how to perform a
venipuncture is provided by CLSI document H3-A6. There
are advantages and disadvantages for both serum and
plasma, which can fluctuate based on the specific marker
of interest (e.g. see Rai and Vitzthum [37]).
The site used for blood withdrawal is also an important
aspect to consider [86]. The median cubital vein, usually
easily found and accessed, is considered the preferred site.
The preparation of the blood collection sites necessitates
an accurate cleaning of the skin with alcohol (2-propanol)
that should be allowed to evaporate, given that the contami-
nation of blood with residual alcohol may induce hemolysis,
increase the concentrations of some analytes, therefore, pro-
ducing interferences [87]. In addition, the position of the pa-
tient (standing, lying, and sitting) can have an impact on the
hematocrit, and, thus, may cause fluctuations in the levels of
the analytes [88].
Moreover, the collection tube can significantly have an
affect the obtained results [37,82]. In fact, tube
components of rubber stoppers, tube wall materials,surfactants, anticoagulants, separator gels, clot activators,
anticoagulants can all impact assay results [82]. To comply
with Occupational Safety and Health Administration (avail-
able at https://www.osha.gov/) guidelines to minimize risks
from shattering tubes, plastic tubes have replaced glass
collection tubes [82,89]. Although plastic tubes offer many
advantages, such as increased gas and water permeability,
they also offer several disadvantages such as the adhesion
of proteins to tube walls [82], which has been an issue iden-
tified for CSFAD biomarkers [90–93]. A detailed review of
the impact of tube components on blood-based assay perfor-
mance has been published by Bowen 2010 [82]. The order of
tube collection in blood draw is also important (CLSI H3-A6
and Rai and Vitzthum [37]) and the current recommenda-
tions can be found in Fig. 1.3.3. Blood processing
CLSI H18-A4 provides detailed information regarding
procedures for handling and processing blood specimens
for laboratory tests. The time considerations from blood-
draw to storage, storage temperature, centrifugation param-
eters, storage volume and container type are all important for
sample processing [37,44,79,94,95]. A key point for
consideration is the separation of the sample from the
tubes immediately after centrifugation. Although the
processing time may vary by study and the importance by
protein being measured, one should not store aliquots from
serum/plasma that have been in contact with cells for more
than two hours [79]. Review of Table 1 shows that most
ongoing protocols require the total processing time to be
2 hours or less, which is preferable. See H18-A4 for a
detailed list of uncentrifuged specimen stability for a range
of times and sample types. Per H18-A4, centrifugation pa-
rameters that should not be subject to variation are: horizon-
tal rotors should be utilized and first centrifugation speed
should be at 2000g for 10 min [50]. Parameters that are sub-
ject to variation but should be documented include: (1) pres-
ence and type of separator, (2) temperature of centrifugation,
and (3) number of centrifugations (single or double). With
regards to postcentrifugation processing, the parameters
that should not be subject to variation include: (1) serum/
plasma is not to be heated or otherwise inactivated, and (2)
no storage at 220

C. Parameters subject to variation but
requiring documentation include: (1) type of secondary
container (tube, straw), (2) time interval between centrifuga-
tion and freezing, (3) sample temperature before aliquoting
and freezing, (4) storage temperature, (5) number of freeze/
thaw cycles, and (6) duration of storage [50,79].
Polypropylene tips and tubes are recommended to reduce
adherence of analytes to walls.3.4. Storage
It has been well acknowledged that protein stability and
enzymatic activity are strictly dependent on temperature
Table 2
Summary of select preanalytical processing elements across ongoing cohorts
Cohort Fasting Needle Serum Plasma Centrifuge Speed/Time Processing time
Storage method
(immediate)
Storage method
(long-term)
TARCC [25,26,31,66] No ND Serum-separating
tubes (tiger tops)
BD EDTA tubes
(purple top)
1300! g/10 min;
room temperature
2 h; sample
processing started
within 1 h of draw
Frozen on wet ice if
unable to be frozen
immediately; placed
in 220C freezer
280C
ADNI [57] Yes 21G (plain red tops) EDTA tubes 3000 rpm/15 min 2 h; sample
processing started
within 1 h following
blood draw
Frozen on dry ice for
20 minutes then
shipped same day;
on arrival samples are
thawed, realiquoted
and placed in 280C
280C
AIBL [58,59] Yes 21G Sarstedt s-monovette
serum-gel (brown
top)
a) Sarstedt s-monovette
lithium heparin
(green top)
b) Sarstedt s-monovette
EDTA tubes (with
PGE added) (purple
top)
Serum: 1800! g/15
minutes 20 C
Plasma: step1:
200 g/10 min
20 C, step2:
800 g/15 min 20C
Total processing must
be completed within
3.5 h; blood
processing must be
started within 20 min
of after blood draw
Frozen immediately at
280C
Liquid
nitrogen
ADCS [56] ND ND EDTA tubes 3000 rpm/10 min ND 280C 280C
NIA Best Practice
Guidelines [65]
Ideal but not
required
Small gauge
needle
ND EDTA or heparin tubes ND ND Quick freeze with dry
ice, then placed
in 280C freezer
280C
HABLE [63] Yes 21G Serum-separating
tubes (tiger tops)
BD EDTA tubes
(purple top)
1300! g/10 min
room temperature
2 h; sample processing
started within 1 h of
draw
280C 280 C
DIAN [60,61] Yes 21G butterfly Red top plain tubes EDTA tubes
(lavender top)
2000! g/15 min
room temperature
Process serum after
allowing to sit at
room temperature
for 30 min
Flash freeze on dry ice
at site, shipped, stored
at 280C, thawed,
aliquot, re-flash frozen
on dry ice and stored at
280C
280C
Liquid
nitrogen
(subset)
ACS [67,68] Yes 21G butterfly N/A EDTA tubes 2000! g/15 min 4C Within 1–2 h of
collection
Receive samples on wet
ice, aliquot, placed in
280C freezer/liquid
nitrogen
284C
Liquid
Nitrogen
(subset)
King’s Dementia
Studies [64]
Yes 21G or 23G
(depending on
vein size)
Serum tube (gold
top)
EDTA tubes (purple top) 3000 rpm/8 min Time from blood draw
to samples freezing
kept within 2–3 h
280 C 280C
Alzheimer Center
Amsterdam [55]
No 21 G BD (also
22,23 G present).
BD serum gel
tubes (red top)
BD EDTA tubes (purple
top)
1800 g/10 min 40C ,2 h, usually
within 1 h.
Immediately frozen
at 280C
280C
Abbreviations: EDTA, ethylenediamine tetraacetic acid; ND, not documented in protocol.
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Fig. 1. Preanalytic processing guidelines.
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
C or liquid nitro-
gen. According to Rai and colleagues [50], liquid nitrogen
storage should represent an excellent system to ensure protein
stability. However, thisway is not often practicable in compar-
ison with the availability of280C freezers. Hence, the long-
term storage temperature should be set at 280C, using
freezers whose temperature oscillations are absent or
extremely diminished. If storage on dry ice is utilized for ship-
ment, the headspace should be vented or the sample should be
allowed to sit in270

C freezer for nine hours before thaw to
facilitate protein stability [97]. Fig. 1 provides the proposed
guidelines for preanalytical processing outlined here.4. Minimum data required for publication
For attempts to be made at cross-validation of biomarker
findings across cohorts and laboratories, a minimum amountof information is required in addition to utilizing common
methods. The select preanalytical elements outlined above
need to be made available to the scientific community within
the manuscript or online supplement. Fig. 1 not only pro-
vides the current guidelines, but also a template for provision
of key preanalytic elements to be provided within publica-
tions for use by other teams.5. Elderly- and dementia-specific preanalytic processing
variables requiring additional research
Although the current guidelines provide the first-step in
the process toward the generation of standards for the field,
there remain several topics that require additional research.
Most importantly relates to the question of how these prea-
nalytical methods require modification for geriatric popula-
tions. For example, the World Health Organization points
Fig. 1. (continued).
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sampling among elderly patients [98]. However, a system-
atic study of the impact of the proposed guidelines specif-
ically among the elderly has not been undertaken. In fact,
review of the previously published materials (including
CLSI documents) does not provide information that is age
specific. Therefore, it is recommended that the need for spe-
cific alterations in the guidelines for the target population be
undertaken with the current guidelines as a starting frame-
work.6. Conclusions and future perspectives
For blood-based biomarker work in AD to progress, there
is a need for the adoption of guidelines to standardize prea-
nalytical methods across cohorts and laboratories [5,42].
Such guidelines will allow for validation or cross-
validation across laboratories and cohorts to further validate
the clinical performance of putative markers where signals
have been established. The current guidelines are an attempt
to verify such existing putative markers for specific clinical
utilities and are not intended to stifle in any way new discov-
eries, which are certainly needed in the blood-based AD
biomarker arena. The Blood Based Biomarkers (PIA) of IS-
TAART combined the efforts of the STAR-B and BBBIG
working groups for a single cohesive effort. This working
group recently published a position article on the future of
blood-based biomarkers of AD in which several needed
areas of work were outlined, which included the need for
guidelines and standards for preanalytical methods [5].The current project reflects the continued efforts of that
working group and development of the first such interna-
tional guidelines for preanalytical processing of bloods in
AD research. It is anticipated that these guidelines will be
updated as needed based on advancements of the field.
There are multiple potential clinical utilities for blood-
based AD biomarkers, and the study design must be reflec-
tive of that particular purpose. For example, blood-based
AD biomarkers of disease presence, amyloid positivity,
CSF biomarker positive (i.e. diagnostic markers) may be
developed within clinic settings of case-control designs;
however, if such markers are to be clinically useful in pri-
mary care settings, they must be tested and evaluated within
such settings as the diagnostic accuracy will vary greatly due
to the difference in disease base rates and diagnostic practice
[99–101]. To date, no such studies have been carried out
validating putative blood-based AD biomarkers within pri-
mary care settings. Issues around analytical assay validation,
discovery versus clinical diagnostic-grade platforms, etc.
have also received little attention. As with preanalytical pro-
cessing variables, CLSI guidelines are currently available
for assessing performance of assays (e.g. EP5, EP6, EP7,
EP10, EP14, EP15, EP17, ILA21, ILA23), which should
be followed if the assay is to move toward clinical applica-
tion.
To date, there are numerous signals for putative blood-
based biomarkers and biomarker panels, although no
consensus has been reached so far following Institute of
Medicine (IOM) guidelines [102]. The purpose of the provi-
sion of the current guidelines from the international working
S.E. O’Bryant et al. / Alzheimer’s & Dementia 11 (2015) 549-560 557group is to begin the process and dialogue of moving toward
standardized methods that can be utilized to move putative
blood-based biomarkers closer to clinical or additional
research practices. An important step will be the detailed
disclosure of the preanalytic parameters used for collection
of clinical samples in publications of the clinical evaluation
of biomarkers. The current document provides information
regarding the minimum necessary information regarding
these preanalytic methods used to facilitate cross-
validation of methods across research teams. Additional
working group documents will address both analytic and
postanalytic variables.Acknowledgments
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1. Systematic review: Recent research points toward
many promising signals in the search for blood-
based biomarkers for Alzheimer’s disease (AD).
However, there remain inconsistencies and failures
to replicate in the literature. With the increased
emphasis from the National Institutes of Health on
increasing the reproducibility of science, there is a
great need for guidelines in this line of research,
similar to ongoing initiatives in neuroimaging and
cerebrospinal fluid biomarkers.
2. Interpretation: There are currently many different
protocols for the preanalytic processing of blood
samples in AD biomarker work. Guidelines were
generated by this international working group as
was a minimum set of information that warrants in-
clusion in research publications.
3. Future directions: These guidelines will provide a
starting-point for the harmonization of procedures
for the validation phase of blood-based biomarker
science in AD. As new research becomes available,
these guidelines will be updated as needed.References
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